Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale

Clinical Chemistry

Volumn 59, Issue 6, 2013, Pages 938-948

  White, Helen E ^a,b   Hedges, John ^c   Bendit, Israel ^d   Branford, Susan ^e   Colomer, Dolors ^f   Hochhaus, Andreas ^g   Hughes, Timothy ^e   Kamel Reid, Suzanne ^h   Kim, Dong Wook ⁱ   Modur, Vijay ^j,p   Müller, Martin C ^k   Pagnano, Katia B ^l   Pane, Fabrizio ^m,n   Radich, Jerry ^o   Cross, Nicholas C P ^a   Labourier, Emmanuel ^b  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ASURAGEN INC   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f HOSPITAL CLÍNIC   (Spain)

^g JENA UNIVERSITY HOSPITAL   (Germany)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ The Catholic University of Korea   (South Korea)

^j Novartis Oncology   (United States)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l UNIVERSITY OF CAMPINAS   (Brazil)

^m UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁿ CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^o Fred Hutchinson Cancer Research Center   (United States)

^p HTG Molecular Diagnostics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ANALYTIC METHOD; ARTICLE; CALIBRATION; CALIBRATOR; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MEASUREMENT ACCURACY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STANDARDIZATION; VALIDITY;

GENES, ABL; GENETIC TESTING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REFERENCE STANDARDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX;

EID: 84878431514     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.196477     Document Type: Article

References (32)

1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51.
2. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999;107:587-99.
3. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999;13:1825-32. (Pubitemid 29535267)
4. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37. (Pubitemid 43990609)
5. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925-30. (Pubitemid 44614879)
6. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32. (Pubitemid 37211057)
7. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
8. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232-8.
9. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for longterm progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-102.
10. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330-8.
11. Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009;23:1957-63.
12. Clark R, Jack A, Holden L, Barnett D, Reilly JT. BCR-ABL quantitation: To is or not to is, that is the question? [Abstract]. Haematologica 2011;96(Suppl 2):S82.
13. Ramsden SC, Daly S, Geilenkeuser WJ, Duncan G, Hermitte F, Marubini E, et al. EQUAL-quant: an international external quality assessment scheme for real-time PCR. Clin Chem 2006;52:1584-91. (Pubitemid 44148322)
14. Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-Reid S. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn 2007;9:421-30. (Pubitemid 47434107)
15. Muller MC, Saglio G, Lin F, Pfeifer H, Press RD, Tubbs RR, et al. An international study to standardize the detection and quantitation of BCRABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica 2007;92:970-3. (Pubitemid 350144244)
16. Saldanha J, Silvy M, Beaufils N, Arlinghaus R, Barbany G, Branford S, et al. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia 2007;21:1481-7. (Pubitemid 46965290)
17. 1st WHO International Genetic Reference Panel for quantitation of BCR-ABL translocation by RQPCR. NIBSC code 09/138. Instructions for use. Herfordshire, UK: NIBSC; 2010.
18. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010;116:e111-7.
19. Hietala SK, Crossley BM. Armored RNA as virus surrogate in a real-time reverse transcriptase PCR assay proficiency panel. J Clin Microbiol 2006;44:67-70. (Pubitemid 43100581)
20. Madej RM, Davis J, Holden MJ, Kwang S, Labourier E, Schneider GJ. International standards and reference materials for quantitative molecular infectious disease testing. J Mol Diagn 2010;12:133-43.
21. Walkerpeach CR, Pasloske BL. DNA bacteriophage as controls for clinical viral testing. Clin Chem 2004;50:1970-1. (Pubitemid 39425830)
22. Brown JT, Laosinchai-Wolf W, Hedges JB, Watt CD, Van Deerlin VM, Fletcher L, et al. Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale. Blood Cancer J 2011;1:e13.
23. Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2008;10:203-11. (Pubitemid 351692162)
24. Pasloske BL, DuBois DB, Brown DM, Winkler M. Ribonuclease resistant RNA preparation and utilization. United States patent US 7,033,749.
25. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135- 60.
26. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)- a Europe Against Cancer program. Leukemia 2003;17:2474-86. (Pubitemid 38072587)
27. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57. (Pubitemid 38072573)
28. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006;125:69-92.
29. Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L, et al. The significance of BCR-ABL molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001;98:1701-7.
30. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26:2172-5.
31. Winn-Deen ES, Helton B, Van Atta R, Wong W, Peralta J, Wang J, et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem 2007;53:1593-600. (Pubitemid 47340054)
32. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res 2011;17:1674-83.